BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11759818)

  • 1. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?
    Kasimir-Bauer S; Oberhoff C; Sliwinska K; Neumann R; Schindler AE; Seeber S
    Breast Cancer Res Treat; 2001 Sep; 69(2):123-32. PubMed ID: 11759818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of rare human breast cancer cells. Comparison of an immunomagnetic separation method with immunocytochemistry and RT-PCR.
    Berois N; Varangot M; Osinaga E; Babino A; Caignault L; Musé I; Roseto A
    Anticancer Res; 1997; 17(4A):2639-46. PubMed ID: 9252694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood.
    Naume B; Borgen E; Beiske K; Herstad TK; Ravnås G; Renolen A; Trachsel S; Thrane-Steen K; Funderud S; Kvalheim G
    J Hematother; 1997 Apr; 6(2):103-14. PubMed ID: 9131439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies.
    Weihrauch MR; Skibowski E; Draube A; Geller A; Tesch H; Diehl V; Bohlen H
    Clin Exp Metastasis; 2002; 19(7):617-21. PubMed ID: 12498391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
    Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
    Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation.
    Naume B; Borgen E; Nesland JM; Beiske K; Gilen E; Renolen A; Ravnås G; Qvist H; Kåresen R; Kvalheim G
    Int J Cancer; 1998 Nov; 78(5):556-60. PubMed ID: 9808522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.
    Slade MJ; Smith BM; Sinnett HD; Cross NC; Coombes RC
    J Clin Oncol; 1999 Mar; 17(3):870-9. PubMed ID: 10071278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
    Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
    Urol Res; 1999 Oct; 27(5):285-90. PubMed ID: 10644227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
    Kasimir-Bauer S; Otterbach F; Oberhoff C; Schmid KW; Kimmig R; Seeber S
    Int J Mol Med; 2003 Dec; 12(6):969-75. PubMed ID: 14612976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.
    Choesmel V; Pierga JY; Nos C; Vincent-Salomon A; Sigal-Zafrani B; Thiery JP; Blin N
    Breast Cancer Res; 2004; 6(5):R556-70. PubMed ID: 15318937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.
    Janni W; Gastroph S; Hepp F; Kentenich C; Rjosk D; Schindlbeck C; Dimpfl T; Sommer H; Braun S
    Cancer; 2000 May; 88(10):2252-9. PubMed ID: 10820346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.
    Naume B; Borgen E; Kvalheim G; Kåresen R; Qvist H; Sauer T; Kumar T; Nesland JM
    Clin Cancer Res; 2001 Dec; 7(12):4122-9. PubMed ID: 11751511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
    Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.
    Schindlbeck C; Stellwagen J; Jeschke U; Karsten U; Rack B; Janni W; Jückstock J; Tulusan A; Sommer H; Friese K
    Clin Exp Metastasis; 2008; 25(3):233-40. PubMed ID: 18185913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemical detection of circulating esophageal carcinoma cells by immunomagnetic separation.
    Nakamura T; Yasumura T; Hayashi K; Eguchi R; Ide H; Takasaki K; Kasajima T
    Anticancer Res; 2000; 20(6C):4739-44. PubMed ID: 11205210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
    Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
    Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.